BNP Paribas Exane upgraded Nebius to Outperform from Neutral and raised its price target to $399 from $260, according to a note from the French investment bank's research desk.
The $139 increase in the target price represents a 53% upside from the prior level. Nebius, the Russian-founded infrastructure company traded on Nasdaq under the ticker NBIS, has drawn institutional attention as a provider of GPU and AI compute capacity to the broader artificial intelligence sector.
BNP Paribas Exane is one of the major equity research franchises globally and typically reaches institutional investors and algorithmic trading desks through subscription-based terminals. The firm's upgrade follows a period of volatility in AI-infrastructure equities as capital markets have sorted through which compute providers hold durable competitive positions amid rapid spending cycles in model development and deployment.
Nebius was spun out of Yandex, Russia's largest search engine, in 2024 and relocated its primary operations and listing to the United States. The company operates data centers across multiple geographies and rents compute infrastructure to customers including cloud platforms and AI research organizations.
Equity research upgrades from bulge-bracket and upper-tier independent franchises like BNP Paribas Exane move trading volume and influence fund positioning, particularly when accompanied by material target-price increases. An upgrade to Outperform means the researcher expects the stock to outperform its relevant peer group or broader index over the next 12 months.
The $260 prior target implied modest upside when set against the stock's trading price at the time. A $399 target at current levels would require a stock move significantly in excess of recent volatility. BNP Paribas Exane's research team has assigned material probability to a faster adoption curve or higher pricing power in GPU infrastructure over its forecast window.
The 53% increase in the target price follows a recalibration of the researcher's baseline case for revenue or margin trajectory, or both. Institutional investors typically weight such upgrades from established research franchises as part of their mosaic approach to stock selection, though the elevation of a single target does not constitute a consensus shift among all research providers covering the name.
